Seaport Therapeutics, the startup launched earlier this year by the team behind Karuna Therapeutics, has raised another $225 million just six months after its most recent fundraising round.
Seaport raised the Series B funds from General Atlantic, Foresite Capital, T. Rowe Price Associates, and other investors. The startup, which is based in Boston, is developing a new cohort of what executives hope will be faster-acting, more effective treatments for depression, anxiety, and other mental health conditions.
It is developing oral treatments where the ingredients are steered toward the lymphatic system, rather than the body’s natural filter and detoxification center: the liver. The founders hope that bypassing the liver will allow more of the medication to circulate in the body and hit nervous system receptors, such as the GABA receptor.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in